Literature DB >> 10786676

WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.

A K Bednarek1, K J Laflin, R L Daniel, Q Liao, K A Hawkins, C M Aldaz.   

Abstract

Studies were conducted with the final goal of identifying genes of interest mapping to the chromosome region 16q23.3-24.1, an area commonly affected by allelic losses in breast cancer. To this end we generated a detailed physical map of the genomic region spanning between sequence-tagged site markers D16S518 and D16S516. To identify candidate genes, we used shotgun genomic sequencing as well as isolation and analysis of transcripts mapping to the area of interest. We identified and cloned a novel gene, the genomic structure of which spans the whole region of interest. We named this gene WWOX because it contains two WW domains coupled to a region with high homology to the short-chain dehydrogenase/reductase family of enzymes. The ORF of WWOX is 1245 bp long, encoding a 414-amino acid protein. This gene is composed of nine exons. We performed a mutation screening of WWOX exons in a panel of breast cancer lines, most of which are hemizygous for the 16q genomic region indicated. We found no evidence of mutations, thus indicating that WWOX is probably not a tumor suppressor gene. However, we observed that one case of homozygous deletion as well as two previously described translocation breakpoints map to intronic regions of this gene. We speculate that WWOX may span the yet uncharacterized common fragile site FRA16D region. In expression studies we found overexpression of WWOX in breast cancer cell lines when compared with normal breast cells and tissues. The highest normal expression of WWOX was observed in hormonally regulated tissues such as testis, ovary, and prostate. This expression pattern and the presence of a short-chain dehydrogenase/reductase domain and specific amino acid features suggest a role for WWOX in steroid metabolism. Interestingly, the presence of WW domains in the structure of WWOX indicate the likelihood that this protein physically interacts with other proteins. The unique features of WWOX and its possible association with cancer processes make it an interesting target for further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786676

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  161 in total

1.  Short-chain dehydrogenase/reductase (SDR) relationships: a large family with eight clusters common to human, animal, and plant genomes.

Authors:  Yvonne Kallberg; Udo Oppermann; Hans Jörnvall; Bengt Persson
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

3.  A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development.

Authors:  Stefan White; Jacqueline Hewitt; Erin Turbitt; Yvonne van der Zwan; Remko Hersmus; Stenvert Drop; Peter Koopman; Vincent Harley; Martine Cools; Leendert Looijenga; Andrew Sinclair
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

4.  Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer.

Authors:  Yulong Zhou; Yongjian Xu; Zhenxiang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 5.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

6.  Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo.

Authors:  Rami I Aqeilan; John P Hagan; Haifa A Aqeilan; Flavia Pichiorri; Louise Y Y Fong; Carlo M Croce
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

Review 7.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

8.  Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype.

Authors:  Suhaib K Abdeen; Sara Del Mare; Sadeeq Hussain; Muhannad Abu-Remaileh; Zaidoun Salah; John Hagan; Maysoon Rawahneh; Xin-An Pu; Stacey Russell; Janet L Stein; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

Review 9.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

10.  Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours.

Authors:  D Ramos; M Abba; J A López-Guerrero; J Rubio; E Solsona; S Almenar; A Llombart-Bosch; C M Aldaz
Journal:  Histopathology       Date:  2008-04-29       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.